Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 S249C |
| Therapy | Fexagratinib |
| Indication/Tumor Type | urinary system cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 S249C | urinary system cancer | sensitive | Fexagratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Fexagratinib (AZD4547) decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245). | 27401245 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27401245) | c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. | Full reference... |